查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1722876

2025 年至 2033 年抗肥胖藥物市場規模、佔有率、趨勢及預測（依藥物類別、藥物類型、配銷通路及地區分類）

Anti-Obesity Drugs Market Size, Share, Trends and Forecast by Drug Class, Drug Type, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球抗肥胖藥物市場規模價值 25 億美元。展望未來， IMARC Group估計到 2033 年市場規模將達到 59 億美元，2025 年至 2033 年的複合年成長率為 9.89%。北美目前佔據市場主導地位，2024 年的市佔率將超過 36.7%。由於肥胖率上升、健康意識增強、對體重管理解決方案的需求、藥物開發的進步、政府舉措、研發投資、聯合療法以及處方藥和非處方藥的可用性，抗肥胖藥物的市場佔有率正在增加。

減肥藥的目的是減少或控制體重，一般只在病態肥胖的情況下才開處方。它們有助於減少食慾並控制強迫性飲食，特別是對甜食、油膩、鹹味和高熱量食品的渴望。它們還可以提供獨立的健康益處，例如控制血壓、有害脂質水平、腰圍、血糖水平和非酒精性脂肪肝病（NAFLD），並最大限度地降低主要心血管疾病（CVD）和糖尿病腎病變進展的風險。

抗肥胖藥物市場趨勢：

抗肥胖藥物的最新進展使得個人有可能實現臨床上顯著的減肥效果。這與久坐不動的生活方式導致的肥胖症的普遍流行相結合，是創造積極市場前景的關鍵因素之一。此外，肥胖會增加罹患第 2 型糖尿病 (T2D)、心血管疾病 (CVD) 以及食道癌、結腸癌、直腸癌、肝癌、膽囊癌、胰臟癌和腎癌的風險。它還會導致許多心理、神經、肺、胃腸道、腎臟、肌肉骨骼和內分泌疾病。除此之外，睡眠不足、晝夜節律不同步、慢性壓力以及抗癲癇和精神藥物的使用增加都可能進一步導致體重增加。再加上有助於調節食慾和食物渴望的抗肥胖藥物（AOM）的批准數量不斷增加，推動了市場的成長。除此之外，減重有助於改善個人的生活品質、活動能力、日常功能和心理健康。預計這一趨勢，加上人們健康意識的增強、製藥業的蓬勃發展以及對與體重超重密切相關的疾病管理的日益關注，將刺激市場的成長。

本報告回答的關鍵問題

  • 減肥藥市場有多大？減肥藥市場未來前景如何？
  • 推動抗肥胖藥物市場發展的關鍵因素有哪些？
  • 哪個地區佔減重藥物最大的市場佔有率？
  • 全球抗肥胖藥物市場領先的公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球抗肥胖藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥品類別

  • 周邊作用藥物
  • 中樞作用藥物

第7章：市場區隔：依藥物類型

  • 處方藥
  • 非處方藥

第8章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Gelesis
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Norgine BV
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Rhythm Pharmaceuticals Inc.
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus LLC
Product Code: SR112025A5544

The global anti-obesity drugs market size was valued at USD 2.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 5.9 Billion by 2033, exhibiting a CAGR of 9.89% from 2025-2033. North America currently dominates the market, holding a market share of over 36.7% in 2024. The anti-obesity drugs market share is increasing due to the rising obesity rates, health awareness, demand for weight management solutions, drug development advancements, government initiatives, R&D investments, combination therapies, and availability of prescription and over-the-counter drugs.

Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.

Anti-Obesity Drugs Market Trends:

Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.

Key Market Segmentation:

Breakup by Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Breakup by Drug Type:

  • Prescription Drugs
  • OTC Drugs

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Key Questions Answered in This Report

  • 1.How big is the anti-obesity drugs market?
  • 2.What is the future outlook of anti-obesity drugs market?
  • 3.What are the key factors driving the anti-obesity drugs market?
  • 4.Which region accounts for the largest anti-obesity drugs market share?
  • 5.Which are the leading companies in the global anti-obesity drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Obesity Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Peripherally Acting Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Centrally Acting Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Prescription Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 OTC Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Boehringer Ingelheim International GmbH
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Currax Pharmaceuticals LLC
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Gelesis
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 GlaxoSmithKline plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Norgine B.V.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Novo Nordisk A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Rhythm Pharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 SHIONOGI & Co. Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Vivus LLC
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Anti-Obesity Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Obesity Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Anti-Obesity Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Anti-Obesity Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 5: Global: Anti-Obesity Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Anti-Obesity Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Anti-Obesity Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Anti-Obesity Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Anti-Obesity Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Anti-Obesity Drugs (OTC Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Anti-Obesity Drugs (OTC Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Anti-Obesity Drugs (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Anti-Obesity Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Anti-Obesity Drugs (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Anti-Obesity Drugs (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: North America: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: North America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: United States: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: United States: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Canada: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Canada: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Asia-Pacific: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Asia-Pacific: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: China: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: China: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Japan: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Japan: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: India: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: India: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: South Korea: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: South Korea: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Australia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Australia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Indonesia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Indonesia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Europe: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Europe: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Germany: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Germany: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: France: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: France: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: United Kingdom: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: United Kingdom: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Italy: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Italy: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Spain: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Spain: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Russia: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Russia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Latin America: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Latin America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Brazil: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Brazil: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Mexico: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Mexico: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Middle East and Africa: Anti-Obesity Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Middle East and Africa: Anti-Obesity Drugs Market: Breakup by Country (in %), 2024
  • Figure 70: Middle East and Africa: Anti-Obesity Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Anti-Obesity Drugs Industry: SWOT Analysis
  • Figure 72: Global: Anti-Obesity Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Anti-Obesity Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Obesity Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Anti-Obesity Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Anti-Obesity Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Anti-Obesity Drugs Market: Competitive Structure
  • Table 7: Global: Anti-Obesity Drugs Market: Key Players